Each year, bladder cancer is diagnosed in approxi mately 430,000 patients worldwide, with urothelial carcinoma (also known as transitionalcell carcinoma) being the predominant histological subtype in the USA and Europe 3 . Approximately 70% of patients with blad der cancer present with nonmuscleinvasive disease (NMIBC) and have an excellent prognosis, with 5year overall survival approaching 90% 4, 5 (TABLE 1) . Most nonmuscleinvasive tumours are low grade and harbour genetic mutations that result in constitutive activation of receptor tyrosine kinase (RTK)/RAS/PI3K signalling pathways 6, 7 . The remaining 20-40% of patients either present with muscleinvasive or advancedstage disease (TABLE 1) , or have disease progression after treatment of nonmuscleinvasive disease; many of these patients have highgrade tumours driven by loss of tumour suppressor genes (such as TP53, RB1 and/or PTEN), which have a propensity for local and distant spread 6 . Once the disease becomes metastatic, 5year overall survival is a dismal 6% 5 ; therefore, treatment of muscleinvasive bladder cancer (MIBC; cT2T4a, cN0M0) is an important opportunity to avoid metastasis and achieve cure.
Despite primary surgical management of MIBC with radical cystectomy and pelvic lymphnode dissection, up to 50% of patients will eventually develop tumours at distant sites, owing to preexisting disseminated occult micrometastases 8, 9 . Thus, local and systemic thera pies must be combined to improve outcomes. In this Review, we describe the evolution of the chemother apy landscape in the perioperative treatment of MIBC. Neoadjuvant cisplatinbased chemotherapy has emerged Abstract | Many patients diagnosed with muscle-invasive bladder cancer (MIBC) will develop distant metastatic disease. Over the past three decades, perioperative cisplatin-based chemotherapy has been investigated for its ability to reduce the number of deaths from bladder cancer. Insufficient evidence is available to fully support the use of such chemotherapy in the adjuvant setting; however, neoadjuvant cisplatin-based combination chemotherapy has become a standard of care for eligible patients based on the improved disease-specific and overall survival demonstrated in two randomized phase III trials, compared with surgery alone. For patients with disease downstaging to non-MIBC at the time of radical cystectomy as a result of neoadjuvant chemotherapy, outcomes are outstanding, with 5-year overall survival of 80-90%. Nevertheless, the inability to define before treatment the patients who will and those who will not achieve such a response has impeded the achievement of better outcomes for patients with MIBC. High-throughput DNA and RNA profiling technologies might help to overcome this barrier and enable a more-personalized approach to the use of cytotoxic neoadjuvant chemotherapy. In the past 2 years, trial results have demonstrated the unprecedented ability of immunecheckpoint blockade to induce durable remissions in patients with metastatic disease that has progressed after chemotherapy; studies are now urgently needed to determine how best to incorporate this powerful therapeutic modality into the care of patients with MIBC. Herein, we review the evolution of chemotherapy and immunotherapy for muscle-invasive bladder cancer.
as a standard of care [10] [11] [12] [13] , although many patients do not benefit from this approach 14, 15 . Therefore, we high light advances in genomic profiling that might result in more individualized treatment that could improve outcomes. Finally, the potential implications of novel immunotherapies for the future treatment of MIBC are considered.
Timing of perioperative chemotherapy Theory versus practice. Perioperative treatment encom passes the therapies given immediately before or after surgery. In theory, the administration of chemother apy before (neoadjuvant) or after (adjuvant) definitive local therapy should be equally effective in eliminating micrometastases. Indeed, the findings of many large randomized trials of chemotherapy in patients with early stage breast cancer support this hypothesis [16] [17] [18] . Nevertheless, upfront surgery can enable pathological confirmation of the extent of disease before systemic therapy. Of note, between 6% and 15% of patients with MIBC have been reported to achieve a pathological complete response (pCR) with transurethral resection of bladder tumour (TURBT) alone, and these patients have excellent outcomes without chemotherapy 8, 14, 19, 20 . Thus, the ability to use features associated with risk of disease recurrence in order to refine patient selection for treatments, and thereby prevent overtreatment or undertreatment of some patients, is a clear advantage of an adjuvant strategy over the neoadjuvant approach. In practice, however, many of the patients with MIBC who choose to undergo upfront surgery will never actually receive adjuvant chemotherapy. Bladder cancer is largely a disease of the elderly, with a median age at diagnosis of 73 years 21 , and radical cystectomy is a much more mor bid procedure than the local therapies used in patients with early stage breast cancer. For example, the findings of a retrospective study in 1,142 consecutive patients who underwent radical cystectomy indicate that 30% of patients experience a grade 2-5 complication within 90 days of surgery that could delay the delivery of effec tive adjuvant chemotherapy 22 . Thus, the timing of peri operative therapy might be more critical in patients with MIBC than in those with breast cancer, and the proportion of patients with MIBC who receive chemo therapy might be increased using a neoadjuvant, rather than adjuvant, approach.
Poor accrual: the scourge of adjuvant therapy trials in MIBC. Within the past 10 years, four randomized trials evaluating adjuvant chemotherapy for MIBC have been closed early owing to poor patient accrual [23] [24] [25] [26] , collectively achieving <50% of their enrolment tar get (TABLE 2) . EORTC 30994 was the largest and most recently published of these trials 26 . In this trial 26 , 284 patients with pT3-4 and/or lymphnodepositive dis ease were randomly assigned to receive one of three different chemotherapy regimens (either gemcitabine plus cisplatin; methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC); or dosedense MVAC (ddMVAC)), or the same regimens deferred until relapse. At a median followup duration of 7 years, the median overall survival in the immediate treatment group was 6.74 years (95% CI 3.85-not reached) versus 4.60 years (95% CI 2.15-6.25) in the deferred treatment group; however, the difference in overall survival favouring immediate use of chemotherapy did not reach statis tical significance (adjusted hazard ratio (HR) 0.78, 95% CI 0.56-1.08; P = 0.13). Adjuvant chemotherapy did, however, significantly prolong progressionfree survival (PFS): median PFS was 3.1 years with adjuvant therapy versus 0.99 years in the deferred chemother apy group (HR 0.54, 95% CI 0.40-0.73; P <0.0001). In contrast to earlier findings from a metaanalysis 27 and a retrospective study 28 , the patients without lymphnode involvement included in the EORTC 30994 trial had a 5year overall survival benefit from immediate treat ment (HR 0.37, 95% CI 0.16-0.83; P = 0.012), whereas those with lymphnode involvement did not (HR 0.94, 95% CI 0.65-1.34; P = 0.72) 26 . These findings raise the possibility that some patients without lymphnode involvement were classified as such owing to inadequate lymphnode sampling, and that subsequent chemother apy compensated for undetected lymphnode involve ment in these patients -an effect that was not needed in the lymphnodepositive group who underwent morethorough lymphnode dissection.
Given the poor patient accrual and early closure of randomized trials, Galsky et al. 29 used data from the American College of Surgeons and American Cancer Society National Cancer Database (NCDB) to investi gate the benefit associated with adjuvant chemotherapy in patients with pT3-4 and/or lymphnodepositive bladder cancer. A total of 5,653 patients treated between 2003-2006 were identified, of whom 23% had received adjuvant chemotherapy 29 . The authors controlled for multiple factors associated with treatment selection, such as age, sex, pathological tumour stage, income, and insurance status, through the use of propensity scores, and found an improvement in overall survival with the use of adjuvant chemotherapy compared with no chemotherapy (HR 0.70, 95% CI 0.64-0.76) 29 . The benefit of adjuvant chemotherapy was consistent when variables not captured in the NCDB, such as perfor mance status, were accounted for through sensitivity
Key points
• High metastatic relapse rates after radical cystectomy indicate muscle-invasive bladder cancer (MIBC) is a systemic disease at diagnosis in many patients • The use of adjuvant chemotherapy to decrease relapse rates after radical cystectomy is not supported by level 1 evidence, and the postoperative morbidity of patients often precludes such systemic treatment • For eligible patients, the standard-of-care treatment approach for MIBC comprises cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy and bilateral pelvic lymph-node dissection • Barriers to improved patient outcomes include inaccurate clinical staging before selecting curative treatment, slow uptake of neoadjuvant chemotherapy, and the lack of an effective non-cisplatin-based neoadjuvant treatment regimen • Identification of genomic predictors of a response to chemotherapy might lead to a more-personalized approach to the treatment of patients with MIBC • Immunotherapy will probably reshape the MIBC treatment landscape analyses 29 . The adjuvant chemotherapy regimens used, however, are not clearly defined in the NCDB, and infor mation about disease recurrence or the timing of poten tial salvage chemotherapy in patients in the observation group is lacking. Furthermore, results of retrospective analyses are known to be subject to sources of bias and confounding, despite careful controlling for imbalances, and cannot substitute for level 1 evidence, which can only be achieved through prospective randomized trials.
NACT: early lessons learned
The identification and confirmation of an effective NACT regimen for patients with MIBC required over two decades of investigation, with treatment regi mens being extrapolated from the metastatic to the muscle invasivedisease setting (TABLE 3 and TABLE 4 , respectively). Pioneering work in the 1970s and early 1980s established the therapeutic activity of cisplatin in patients with urothelial bladder cancer, and led to its use as a cornerstone of combinatorial regimens for those with metastatic disease [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . After promising results of cisplatinbased combination therapies were demon strated in patients with metastatic disease, the regimens were tested as neoadjuvant treatments in patients with MIBC. Many of the lessons learned during these early experiences remain relevant today.
Beware of clinical understaging in MIBC. In 1988, Scher et al. 40 reported data from 50 patients who had received neoadjuvant treatment with 1-5 cycles of MVAC; of 30 patients who underwent radical cystectomy, 33% achieved a pCR and a further 17% had downstaged dis ease. Importantly, despite extensive reevaluation using TURBT and other clinical staging procedures after NACT, a clinical and pathological staging discrepancy of 38% was observed in this study 40 . Later trials and patient series have continued to report frequent clini cal disease understaging using prechemotherapy and post chemotherapy TURBT, and noninvasive ima ging modalities [41] [42] [43] [44] [45] (TABLE 5) . Thus, at present, patients should proceed to radical cystectomy and bilateral pel vic lymphnode dissection, even if a clinical complete response is achieved with NACT. Indeed, at a consensus meeting held in 2012, a panel of bladder cancer experts stated that placing patients who have achieved a clinical complete response to NACT under observation only is "akin to playing Russian roulette" (REF. 46 ), and did not recommend the approach. Moreover, some centres have advocated using clinical factors to select patients for NACT 45 , but the high discrepancy between clini cal sta ging and actual pathological staging also raises important concerns regarding whether this strategy is appropriate.
Patients with lymph-node involvement during preoperative assessment have stage IV disease and should be treated accordingly. Muscleinvasion alone reflects the capacity of a bladder tumour for distant spread, although lymphnode involvement is a more definitive harbinger of systemic dissemination 8 . In the original trials of the MVAC regimen for the treatment of blad der cancer 40, 47 , patients with suspected lymphnode involvement were included in the metastatic disease cohorts; however, patients with metastases restricted to lymph nodes or softtissue sites can achieve longterm disease control if they experience a major response after six cycles of cisplatinbased combination therapy and then go on to have consolidation surgery, whereas such control of disease is rarely achieved in those with do not have a major response or in patients who have visceral metastases [48] [49] [50] . An analysis of NCDB data, published by Galsky et al. 51 in August 2016, revealed that treatment with perioperative chemotherapy and surgery was associated with better outcomes than either surgery or chemotherapy alone in patients with bladder cancer and clinical evidence of regional lymphnode involvement. Chemotherapy for patients with clinical lymphnode involvement can, therefore, be followed by surgery, but should not be referred to as 'neoadjuvant chemotherapy' -which is defined as four cycles of chemotherapy for cT2-T4aN0M0 disease, rather than six cycles for nodal (N1-3) or metastatic (M1) disease. In the modern era, some data indicate that lymphnode metastases of 1-2 cm in diameter can be effectively evaluated with 52 . Six cycles of cisplatinbased chemotherapy should remain the standardofcare approach for patients with lymph node involvement during preoperative assessment until compelling evidence from randomized clinical trials indicates that overall survival is equivalent with either a shorter duration of chemotherapy or a novel therapeutic approach.
Downstaging to NMIBC after NACT is an intermediate end point for survival.
Another important lesson learned from the early experience with cisplatinbased NACT is that improved overall survival is associated with not only a pCR, but also downstaging to NMIBC with no patho logical lymphnode involvement (<pT2N0) at the time of radical cystectomy. In a retrospective analysis involving 147 patients with MIBC, Splinter et al. 53 reported that 41.5% of patients were downstaged to <pT2N0 after neo adjuvant treatment with MVAC. Notably, 5year overall survival was 75% in this subgroup, compared with 20% among those with residual muscleinvasive tumours (>pT2) or lymphnode involvement at the time of sur gery 53 . Similarly, the findings of a retrospective analysis of a large, randomized trial demonstrated that patients with pathological MIBC and/or nodepositive disease after neoadjuvant MVAC have dismal outcomes 54 . The positive correlation between downstaging to <pT2N0 disease and improved overall survival has also been demonstrated in a retrospective case series 55 and a large metaanalysis 56 . Indeed, phase II neoadjuvant trials with the <pT2N0 rate as an intermediate end point have been proposed as a model for accelerating drug development in MIBC 57, 58 . Despite the fact that patients without downstaging to <pT2N0 after 12 weeks of cisplatinbased NACT have poor outcomes, no highlevel evidence supports the use of additional adjuvant chemotherapy in this population.
Nevertheless, one retrospective study in 37 patients with lymphnode involvement after NACT reported an improvement in diseasefree survival (DFS) with a variety of different 'adjuvant' chemotherapy regimens 59 . While hypothesis generating, this study did not demon strate an overall survival benefit and the results must be confirmed in larger patient cohorts. As discussed in a later section of this Review, novel approaches with immunecheckpoint blockade might prove to be more effective than the use of cytotoxic chemotherapy in this setting.
The use of NACT does not affect the feasibility and safety of surgery. The Nordic Cooperative Bladder Cancer Study Group conducted the first randomized phase III trials of cisplatinbased combination chemotherapy in patients with MIBC. In the Nordic Cystectomy Trial I 60 , 325 patients were randomly assigned to receive either neoadjuvant cisplatin plus doxorubicin or no NACT before undergoing shortterm radiotherapy followed by radical cystectomy (TABLE 4) . In the Nordic Cystectomy Trial II 61 , the efficacy of cisplatin and methotrexate was compared with no pretreatment before radical cystectomy in 317 patients with MIBC. Neither trial demonstrated an improvement in overall survival with NACT, although the combined data from the Nordic trials helped alleviate concerns that NACT might negatively affect the ability to perform a radical cystectomy: radical cystectomy was performed in 86% of patients in the NACT arms and 87% of those in the control arms 60, 61 . The results of the subsequent large (n = 317), multiinstitutional phase III SWOG8710 trial 14 also demonstrated that MVAC did not adversely affect a patient's chance of undergoing cystectomy, and the rate of surgical complications was not increased among the MVACtreated patients versus those who did not receive NACT. NACT improves survival in MIBC Supportive level 1 evidence. In the BA06 30894 trial 62, 63 , a multicentre study performed by an international collab oration of trialists, 976 patients were randomly assigned to receive either three cycles of neoadjuvant cisplatin, methotrexate, and vinblastine (CMV), or no NACT before radical cystectomy and/or radiotherapy. In an updated analysis of this trial after a median followup duration of 8 years 63 , neoadjuvant CMV was associated with an abso lute improvement in 10year survival from 30% to 36% (TABLE 4) , with a corresponding 16% reduction in the risk of death (HR 0.84, 95% CI 0.72-0.99; P = 0.037).
In the pivotal SWOG8710 randomized trial 14 , patients with MIBC received either radical cystectomy alone, or three cycles of MVAC followed by radical cys tectomy (TABLE 4) ; diseasespecific survival was inferior for the patients who received radical cystectomy alone versus those who received neoadjuvant MVAC (HR 1.66, 95% CI 1.22-2.45; P = 0.002) 14 . A trend toward inferior overall survival was also observed for the patients who underwent upfront surgery versus those treated with MVAC (5year overall survival 45% versus 57%; HR 1.33, 95% CI 1.00-1.76; P = 0.06) 14 . In addition, the pCR rate was improved after neoadjuvant MVAC compared with surgery alone (38% versus 15%; P <0.001) 14 . Consistent with prior reports 53 , achieving a pCR to NACT was cor related with an excellent 5year overall survival rate of 85% in the SWOG8710 cohort 14 . Finally, for patients who did not have a pCR at the time of radical cystectomy, those who received neoadjuvant MVAC had a median overall survival that was not significantly different to that observed for those who received upfront radical cystectomy (3.8 years versus 2.4 years).
In 2005, an updated metaanalysis 10 of data from 3,005 patients included in 11 clinical trials revealed a 5% absolute increase in 5year overall survival and a 14% decreased risk of death (HR 0.86, 95% CI 0.77-0.95; P = 0.003) among patients with MIBC who received cisplatin based NACT before local therapy compared with those who received the same local treatments only; this benefit was consistent across patient subgroups defined by age, sex, and clinical T or N category, and a significant DFS benefit of NACT was also observed (HR 0.78, 95% CI 0.71-0.86; P <0.0001). At first glance, these findings could be interpreted as a small, incre mental improvement in outcomes; however, a meta analysis 64 of data from 17,723 women with early stage breast cancer that helped establish adjuvant chemother apy as a standard of care showed a 7% survival benefit and a 15% decrease in breastcancer related mortality for women aged ≤50 years. Similarly, a pooled analysis involving 3,302 patients with colon cancer helped estab lish 5 fluorouracil based adjuvant therapy as a stand ard of care based on a survival benefit of 7% at 5 years. Thus, the survival benefit of cisplatin based NACT for patients with MIBC is comparable to that reported among patients with other tumour types in which peri operative chemotherapy is both statistically and clinically significant, and an accepted standard of care.
Level 1 evidence has not led to widespread implementation of NACT. Despite the availability of level 1 evi dence supporting its ability to improve survival, uptake of cisplatin based NACT for the treatment of MIBC by the oncology and urology communities has been extremely slow. An analysis of NCDB data from 7,161 patients with American Joint Committee on Cancer (AJCC) stage III MIBC (TABLE 1 With the advent of novel chemotherapeutic agents and haematopoietic growth factor support, investigators have focused on developing NACT regimens with similar efficacy, but less toxicity than that of MVAC. Although not necessarily a 'realworld' estimate, findings of a sur gical trial, reported in abstract form at the American Urological Association 2015 annual meeting 69 , demon strated that 187 out of the 381 patients involved (51%) had been treated with NACT. The favourable toxicity profile of modern chemotherapy regimens (as outlined in the following section) is one of the factors that could potentially explain this trend.
Improving on standard NACT with MVAC Gemcitabine and cisplatin. In a large randomized trial in patients with metastatic urothelial carcinoma 70, 71 , the combination of gemcitabine and cisplatin (GC) had similar efficacy and less toxicity than MVAC (TABLE 3) , and thus the GC regimen became a standardofcare treatment for this patient population. Dash et al. 72 per formed a retrospective, singleinstitution analysis of patients with MIBC who received either neoadjuvant GC or neoadjuvant MVAC before radical cystectomy. Among the 42 patients in the GC cohort, 39 (93%) received all four cycles of GC; 15 of these 39 patients (36%) had disease downstaging to <pT2N0 disease at the time of radical cystectomy and remained diseasefree at a median followup duration of 30 months 72 . Similarly, 19 of the 54 MVACtreated patients (35%) had <pT2N0 at the time of radical cystectomy 72 . The pCR rates for the GCtreated and MVACtreated patients were also similar (26% and 28%, respectively).
In a retrospective assessment of 935 patients with MIBC who received NACT followed by radical cystec tomy across 19 centres 56 , the GC regimen was used in 602 patients (64.4%) and MVAC in 183 patients (19.6%). The <pT2N0 rates in the GC and MVAC cohorts were 44.8% and 43.7%, respectively 56 ; the pCR rate in the patients who received GC was 23.9%, compared with 24.5% for those treated with MVAC (P = 0.2). The efficacies of GC and MVAC in the neoadjuvant setting have never been compared directly in a randomized trial, but the favourable toxicity profile of the GC regimen has never theless resulted in its adoption as a standardofcare NACT endorsed by the National Comprehensive Cancer Network (NCCN) 73 . This endorsement is supported by the aforementioned randomized study conducted in the metastatic setting 70 ( . Use of the ddMVAC regimen seemed to be associated with less toxicity and greater clinical activity than treatment with MVAC 76 (TABLE 3) . This finding resulted in ddMVAC being accepted as a standard of care for patients with metastatic bladder cancer 73 . In 2014, two singlearm, prospective studies evalu ating neoadjuvant ddMVAC with GCSF support in the treatment of patients with MIBC were reported simultan eously 77, 78 . Choueiri et al. 77 treated 39 patients with four cycles of ddMVAC, whereas Plimack et al. 78 evaluated three cycles of ddMVAC in 40 patients; the <pT2N0 rates at the time of surgery were 49% and 53%, respectively, and the pCR rates were 26% and 38%, respectively 77, 78 . Importantly, the dosedense approach can decrease the time between the start of MVAC chemotherapy and the point of surgery, with a median time of 9.7 weeks reported in the study by Plimack et al. 78 (compared with 16-19 weeks for the standard regimens 14, 72 ). The results of these two prospective trials 77, 78 (TABLE 4) , as well as those from two retrospective studies 79, 80 , are promising; however, the authors of an editorial 81 , which accompa nied the trial publications, identified issues regarding patient selection that might limit the generalizability of the results. For example, both trials included patients with N1 disease, therapy for whom, as previously dis cussed, cannot truly be considered 'neoadjuvant' . Of note, a comparative effectiveness analysis of GC versus MVAC NACT has been performed across 28 interna tional centres 82 , with 146 patients included in the GC cohort and 66 patients in the MVAC cohort, 51 (77%) of whom received ddMVAC; no stat istically signifi cant difference in the pCR rate or survival between the two cohorts was demonstrated after adjusting for propensity scores 82 . Data from randomized clinical trials comparing GC and ddMVAC therapy are required to confirm the equiva lence of these regimens, in terms of both efficacy and toxicity. In the ongoing SWOG 1314 trial 83 , patients with MIBC are being randomly assigned to neoadju vant GC or ddMVAC treatment arms in order to deter mine the utility of a geneexpressionbased biomarker approach for predicting pCR, but the findings will also provide an estimate of comparative <pT2N0 rates. In addition, a multicentre phase III study is ongoing in France to compare six cycles of ddMVAC with four cycles of GC, using PFS as the primary end point. Unless the results of these trials strongly suggest that ddMVAC has super ior efficacy, neoadjuvant GC will probably remain the standard ofcare treatment for patients with MIBC owing to the morefavourable toxicity profile.
On the basis of the promising activity and toxicity profiles of dosedense GC (ddGC) compared with that of ddMVAC reported in the metastatic setting 84 (TABLE 3) , two prospective, multicentre phase II studies of neoad juvant ddGC (2week cycle) chemotherapy in patients with MIBC have been initiated and reported in abstract form 85, 86 . Plimack et al. 85 reported that, among the first 13 patients treated in one of these trials, two patients had a myocardial infarction resulting in congestive heart failure, one had a deep venous thrombosis (DVT), one had a pulmonary embolus, and one required coronary artery bypass grafting before surgical resection of the tumour 85 . After a subsequent protocol amendment to require cardiac clearance before study entry, further vascular toxicity was seen, with one additional patient having a DVT and another having a stroke 85 . The study was closed before reaching the enrolment target of 44 patients 85 . Of the 31 patients who underwent radi cal cystectomy, 14 (45%) had <pT2N0 disease and 10 (32%) had a pCR 85 . In the second, morerecent, trial, Balar et al. 86 excluded patients with any recent history of a cardiovascular event from the outset, used a higher dose of gemcitabine than that used by Plimack et al. 85 (2,500 mg/m 2 versus 1,200 mg/m 2 ), and administered splitdose cisplatin (35 mg/m 2 on day 1 and 2) instead of the standard single dose (70 mg/m 2 on day 1). Of the 41 patients who underwent radical cystectomy in the study by Balar et al. 86 , 26 (63.4%) had <pT2N0 disease and, importantly, the vascular toxicity was similar to that observed in neoadjuvant trials of standarddose GC chemotherapy. In an intentiontotreat analysis (with patients who refused radical cystectomy counted as nonresponders), the <pT2N0 rate was 56.5% 86 . The fea sibility of drug delivery for ddGC was excellent: patients received a median of six cycles, and 80% received at least five cycles 86 . Thus, the ddGC regimen used in the trial by Balar et al. 86 is a promising neoadjuvant strategy for appropriately selected patients with MIBC.
Non-cisplatin-based NACT. Approximately 30-50%
of patients with MIBC are ineligible for cisplatinbased NACT owing to ageingrelated and diseaseassociated organ impairment 87 
. The utility of non cisplatin based NACT in this population is controversial and is not supported by prospective evidence from ran domized clinical trials. Findings indicate that carbo platin is inferior to cisplatin in the treatment of patients with metastatic disease [88] [89] [90] ; therefore, use of carbopla tin before definitive therapy in the neoadjuvant setting would seem imprudent without strong supporting evi dence. Singlearm, phase II trials with paclitaxel, carbo platin, and gemcitabine 42, 91 , as well as nabpaclitaxel, carboplatin, and gemcitabine 92 , have yielded pathologi cal responses, but at rates less than those expected with the use of cisplatinbased chemotherapy and with higher incidences of haematological toxicity. Current guidelines suggest that noncisplatinbased chemotherapy should only be considered when downstaging of surgically unresectable tumours is the primary objective 13 . Hussain et al. 93 performed a small study to help address the barrier of renal insufficiency in patients with MIBC with a glomerular filtration rate ≥40 ml/min/1.73 m 2 . In this study, splitdose cispla tin (35 mg/m 2 ) and gemcitabine (1,000 mg/m 2 ) were administered on days 1 and 8 of every 21day cycle, for a maxi mum of four cycles. The regimen was well toler ated, with no clinically significant decline in renal func tion reported 93 . Determining the efficacy of the regimen based on the findings of this study is difficult, given the small sample size and the fact that pathological response rates at the time of radical cystectomy were not reported. Nevertheless, selective use of splitdose cisplatin might widen the spectrum of patients who are eligible for cisplatinbased chemotherapy. Age alone is not a criterion for ineligibility to receive cisplatin, although many elderly patients will fall into this category. Given that the median patient age at diag nosis of bladder cancer is 73 years and individuals aged 75-84 years account for the largest percentage of new cases (30%) 21 , an urgent need exists for clinical trials and interventions to improve outcomes in this population 94 . In addition to moreeffective and lesstoxic therapies, a coordi nated multidisciplinary approach, geriatric assess ment tools, and the incorporation of a geriatric oncolo gist can help identify patients with MIBC who are at an increased risk of chemotherapyinduced toxicity [95] [96] [97] .
Predictors of response to NACT
The inability to predict responsiveness to cisplatin based NACT is a major impediment to improving the outcomes of patients with MIBC. In a phase III trial of cisplatinbased adjuvant chemotherapy, investiga tors attempted to determine the utility of p53 positiv ity, assessed using immunohistochemistry, to predict response 24 . Although p53 was not found to be prognos tic, a high patient refusal rate, lower than expected event rate, and failures to receive the assigned therapy severely compromised the statistical power of the study 24 . The current empirical treatment approach results in many patients receiving ineffective and potentially toxic chemotherapy; however, the molecular phenotyping made possible by improved highthroughput profiling technologies might lead to a muchneeded shift toward individualized treatment.
Intrinsic subtypes. Wholegenome profiling of RNA expression (the transcriptome) and the grouping of tumours into basal, luminal, and HER2enriched sub types has already had a major effect on the clinical man agement of patients with breast cancer 98, 99 . For example, NACT benefits primarily patients with basallike or HER2enriched tumours, and not those with luminal tumours [100] [101] [102] . Wholegenome RNAexpression profiling of more than 300 NMIBCs and MIBCs revealed intrinsic sub types of bladder cancer that spanned the spectrum of cell differentiation 103, 104 . Additional investigations using mRNAexpression profiling demonstrated that MIBC can be grouped by differential expression of breast basal and luminal markers 105, 106 , and a p53like subtype of 'luminal' MIBC has also been recognized 105 . Using an RNAsequencing platform (RNAseq), the TCGA investigators interrogated 131 MIBCs and also found that these tumours were enriched for breast basal and luminal markers 107 . The TCGA researchers subdivided the luminal MIBCs into 'cluster I' (luminal, differenti ated, with FGFR3 aberrations and CDKN2A deletions) and 'cluster II' (luminal, less differentiated, with epi thelialtomesenchymal transition (EMT)); cluster II corresponded with the aforementioned p53like sub type 108 . The TCGA consortium also subdivided the basal tumours into 'cluster III' (squamous) and 'clus ter IV' (EMT and immuneinfiltrated) subtypes. The results of an expanded TCGA analysis in an additional 281 patients were reported in abstract form at the 2016 Genitourinary Cancer Symposium and confirmed these four geneexpressionbased MIBC subtypes 109 . Similar to observations in breast cancer, each of the intrinsic subtypes of MIBC seem to have distinct clinical characteristics and prognoses. For example, compared with those with basal MIBCs, patients with luminal MIBCs tend to have better clinical outcomes, with less advancedstage disease at presentation, but are also less chemoresponsive 105, 106 . A retrospective evaluation of patients treated with cisplatinbased NACT suggested that those with p53like luminal MIBCs were chemo resistant and less likely to be of stage <pT2N0 at the time of radical cystectomy than those with other tumour subtypes 105 . Moreover, in a phase II trial evaluating neo adjuvant ddMVAC and bevacizumab, patients with basal tumours exhibited better 5year overall survival rates compared with those with luminal and p53like tumours (91%, 73%, and 36%, respectively) 110 . The findings were externally validated in a historical cohort of 49 patients treated with neoadjuvant MVAC, but the sample size was, nevertheless, small and heterogeneous, and no correlation between intrinsic subtype and pathologi cal response at the time of surgery was reported. Thus, the predictive value of the intrinsic subtypes in MIBC requires additional confirmation.
Alterations in DNA-repair genes. Cisplatin causes intra strand and interstrand DNA crosslinks, which interfere with DNA replication and gene transcription; inability to repair this treatment induced damage has been reported to increase tumourcell sensitivity to cisplatin 111, 112 . Two groups have evaluated whether genomic alterations in DNArepair pathways are predictive of responsiveness to cisplatin based NACT in patients with MIBC 113, 114 (TABLE 6). Van Allen et al. 113 found that inactivating mutations in the nucleotide excision repair (NER) gene ERCC2 were significantly enriched in responders com pared with nonresponders to cisplatinbased NACT (P <0.001; q <0.007); indeed, ERCC2 was the only gene among a panel of 3,277 with possibly consequential somatic alterations that was significantly enriched in responders. Plimack et al. 114 found that the presence of an alteration in one or more of the three DNArepairrelated genes, ATM, RB1, and FANCC, predicted a pathological response (P <0.001 in the discovery cohort; P = 0.033 in the validation cohort).
Box 1 | Criteria for cisplatin ineligibility
Galsky et al. 15 have established a consensus definition for cisplatin ineligibility in patients with bladder cancer based on at least one of the following criteria: The relationship between somatic alterations in DNArepair genes and the intrinsic TCGA subtypes of MIBC has been explored 108, 114 . Plimack et al. 114 evaluated 33 samples from the discovery group that had already been assigned to a TCGA subset and found that the ATM/RB1/FANCC signature did not correlate with the subset assignment. McConkey et al. 108 demonstrated that ERCC2 mutations can be present in tumours from all four TCGA subgroups including, surprisingly, clus ter II tumours -corresponding to the chemoresistant p53like subtype. Thus, further explorations of whether ERCC2mutated, p53like luminal tumours are sensitive or resistant to cisplatinbased NACT will be revealing.
Prospective evaluation of genomic predictors. As men tioned previously, SWOG 1314 is an ongoing clinical trial of GC versus ddMVAC NACT that was designed to prospectively evaluate the ability of a gene expression profiling algorithm (COXEN) to predict patho logi cal responses 115 . In this trial, geneexpression and microRNA expression data, as well as patient samples for tissue microarray construction, are being collected before chemotherapy. The goal is to develop a rational and individualized treatment approach, in which patients who are unlikely to respond to NACT could be advised to undergo immediate radical cystectomy or to receive a novel treatment as part of a clinical trial. Alternatively, bladdersparing approaches could be explored in patients who are predicted to be extremely sensitive to cisplatin.
Immune-checkpoint inhibitors
Despite the aforementioned advancements in the treat ment of bladder cancer, the survival of patients with MIBC has not improved over the past 15 years, and no new drug has been approved in the USA in more than 20 years 3 . This therapeutic stalemate is not dissimilar to the state of treatment for metastatic melanoma in early 2011. Since 2011, however, the treatment armamen tarium for metastatic melanoma has been bolstered by nine different drug approvals by the FDA, most of them immunotherapies. Bladder cancer was actually the first disease for which the FDA approved an immunother apy: intravesical administration of bacillus Calmette Guérin (BCG) was approved in 1990 for the treatment of NMIBC 116, 117 . More recently, antibodies targeting the programmed celldeath protein 1 (PD1)/programmed cell death 1 ligand 1 (PDL1) pathway, which is an inhibi tory immune checkpoint that regulates Tcell activ ity, have demonstrated robust evidence of therapeutic activity in patients with metastatic bladder cancer that has progressed despite treatment with platinumbased chemotherapy [118] [119] [120] [121] [122] [123] (TABLE 7) .
Evidence from the metastatic setting. Tumours can elude immune surveillance and elimination through expression of PDL1, which binds to PD1 on cyto toxic T cells, leading to cytotoxic Tcell deactivation and suppression of Tcell proliferation 124 . Results of the singlearm, multicentre, phase II IMvigor 210 trial 118 of the antiPDL1 antibody atezolizumab for the treat ment of metastatic disease were published in May 2016. The reported objective response rate (ORR) among 311 patients was 15%, with 15 (5%) and 30 (10%) patients achieving complete and partial responses, respectively; at a minimum followup duration of 11.7 months, the median duration of response was not reached, with 38 of the 45 (84%) responders having a maintained response 118 . These findings led to the accelerated approval of this approach by the FDA in May 2016. The results of several singlearm, multicentre, phase I/II trials of other antibodies that target PD1 or PDL1 have also been reported [119] [120] [121] [122] [123] , and are comparable to those of the IMvigor 210 study (TABLE 7) . Importantly, in previously untreated, cisplatinineligible patients with metastatic disease, response rates to atezolizumab 125 and the antiPD1 antibody pembrolizumab 126 of 19.1% and 24%, respectively, have been demonstrated in two phase II trials. These response rates are lower than those seen historically with chemotherapy 127 , although the durability of the responses (the median duration of response was not reached in either phase II study) sug gests that immunotherapy could soon become a first line treatment option in this patient population. Given the strong evidence of clinical activity in the metastatic setting, a logical next step is to use these agents in the treatment of patients with MIBC; indeed, trials of this approach are underway (TABLE 8) .
Moving immune-checkpoint inhibitors into the perioperative setting. When a neoadjuvant treatment exists that improves overall survival, the FDA has recom mended the use of an 'addon' strategy, in which the experimental therapy is given in conjunction with the standardofcare therapy 128 . Indeed, combining antiPD1/PDL1 immuno therapy with cisplatinbased NACT for the treatment of patients with MIBC is an attractive approach, given that both treatments have proven antitumour activity. Two urgent questions must be addressed, however. First, is synergy of the combina tion biologically plausible? Second, are predictive bio markers available to identify the patients who are most likely to benefit? Preclinical evidence is available both for and against a potential synergy between chemotherapy regimens and immunecheckpoint blockade. The effectiveness of GC in treating bladder cancer might derive from an ability to stimulate antitumour immune responses 129 . For example, the gemcitabine included in this regi men can deplete regulatory T (T reg ) cells and myeloid derived suppressor cells (MDSC), and enhances Tcell infiltra tion into tumours in animal models [130] [131] [132] [133] . Moreover, cisplatin has been shown to induce tumourcell sus ceptibility to CD8 + cytotoxic T lymphocyte (CTL) mediated killing 134 . In addition, platinumbased chemotherapy has been shown to be mutagenic 135, 136 . Thus, cisplatin might increase the somatic mutational load in tumour cells and lead to the presentation of neoantigens, thereby enabling recognition of tumours by an immune system activated by PD1/PDL1 block ade. Conversely, the glucocorticoids given to attenuate chemotherapyassociated nausea and the nonspecific genotoxic effects of chemotherapy might hamper the antitumour immune response 137, 138 . Clinical data from patients with nonsmall cell lung cancer (NSCLC) seem to support the safety and efficacy of combination treatment with an antiPD1/PDL1 antibody and chemotherapy. For example, atezolizumab was investigated in combination with carboplatin and either paclitaxel, pemetrexed, or nabpaclitaxel in 37 patients with chemotherapynaive advancedstage NSCLC 139 , and the most frequent allgrade adverse events, regardless of attribution across arms, included those commonly associated with chemotherapy. One patient did experience grade 5 toxicity owing to candid aemia after prolonged neutropenia 139 . Among the 30 patients available for evaluation of efficacy outcomes, the ORR across all arms was an impressive 67% 139 . In a randomized phase II trial evaluating chemotherapy with or without pembrolizumab in 123 patients with advancedstage NSCLC, chemotherapy with PD1 blockade was tolerable and also resulted in a higher ORR than chemotherapy alone (55% versus 29%; P = 0.0016) 140 . Whenever possible, in neoadjuvant trials, investi gators should take advantage of the availability of pre treatment and posttreatment tissue and blood samples to investigate mechanisms of response and resistance. In general, the duration of neoadjuvant treatment in such trials is limited, so as not to delay potentially curative sur gery; however, biomarker analysis in pretreatment and posttreatment tissue can provide valuable information, irrespective of pathological response rates. For example, Liakou et al. 141 found that neoadjuvant administration of ipilimumab, an antibody that blocks the immune checkpoint protein cytotoxic Tlymphocyteassociated protein 4 (CTLA4), led to markedly increased expres sion of inducible costimulator (ICOS) on CD4 + T cells present in the peripheral blood and tumour tissues of patients with cancer. The authors postulated that this finding could potentially be used as a biomarker to guide the dosing and scheduling of ipili mumab. Cisplatinineligible patients with MIBC, for whom no standardofcare perioperative therapy exists, are an ideal target population for this type of investigative approach. The existence of a shortterm inter mediate end point in the form of pathological response at the time (TABLE 7) . Thus, an urgent need exists for the identifica tion of biomarkers beyond PDL1 expression that can help predict treatment outcomes. The authors of the IMvigor 210 trial of atezolizumab in metastatic urothe lial carcinoma evaluated whether TCGA intrinsic sub type and/or mutational load was predictive of a response to this agent 118 . Geneexpression analysis was used to classify the tumours of 195 patients as luminal (n = 73) or basal (n = 122) subtypes, which have unique PDL1 and CD8 + Teffectorcell geneexpression profiles 118 . Responses to atezolizumab were observed across all TCGA disease subtypes, but occurred at a significantly higher rate in patients with the luminal cluster II dis ease subtype: ORR of 34% versus 10% for subtype I, 16% for subtype III, and 20% for subtype IV (P = 0.0017) 118 . Mutational load was estimated in the tumours from 150 patients by examination of a representative panel of 315 cancerrelated genes, and was significantly increased in responders to treatment compared with nonrespond ers (12.4 per Mb versus 6.4 per Mb; P <0.0001) 118 . The association between mutational load and response to atezolizumab was unrelated to TCGA disease subtype (P = 0.22). A biomarker integration tree proposed by the authors suggests that incorporation of informa tion on TCGA geneexpressionbased disease subtype, mutational load, and PDL1 expression could improve the ability to predict a response to PDL1 blockade.
The value of a multibiomarker classifier merits further investigation in larger cohorts and in future studies of immunotherapy, including those planned in the setting of MIBC.
Bladder-sparing treatments for MIBC Despite improvements in surgical techniques, radical cystectomy can lead to substantial morbidity, and not all patients are eligible or willing to undergo the pro cedure. Multimodality therapy incorporating maximal TURBT followed by radiotherapy combined with vari ous forms of chemotherapy has emerged as an alterna tive, organ preserving treatment strategy 144, 145 . Extensive discussion of this approach is outside the scope of this Review, although such treatment can be offered to selected patients with MIBC and is associated with outcomes superior to those of radiotherapy alone 13, 146 . Future research efforts will focus on optimization of the treatment components, as well as the incorporation of predictive biomarkers and novel cytotoxic, targeted, and immunotherapeutic agents.
Conclusions
MIBC is an aggressive systemic disease that requires a multidisciplinary team to coordinate systemic and local treatments. Major strides in improving the outcomes of patients with this disease were made with the advent of cisplatin and cisplatinbased combination regi mens three decades ago. Since then, two randomized trials and a metaanalysis of data from more than 3,000 patients with MIBC have established level 1 evidence for use of cisplatinbased NACT. Many patients with MIBC are, however, ineligible for cisplatinbased therapy and have no evidencedbased systemic treatment options avail able. In theory, adjuvant chemotherapy should be equally as effective as NACT, but in practice many patients experi ence postoperative complications, deterioration of per formance status, or worsening renal function that can all CD137, cluster of differentiation 137 (also known as 4-1BB and tumour necrosis factor receptor superfamily member 9); CTLA-4, cytotoxic T-lymphocyte-associated protein 4; G, gemcitabine; GC, gemcitabine plus cisplatin; MIBC, muscle-invasive bladder cancer; NACT, neoadjuvant chemotherapy; PD-1, programmed cell-death protein 1; PD-L1, programmed cell death 1 ligand 1.
preclude the safe and timely administration of chemo therapy. Adjuvant trials have failed to reach accrual targets and, although potentially compelling, data from retrospective analyses are not a replacement for prospec tive evidence from randomized clinical trials. Updated consensus guidelines recommend that clinicians have a detailed discussion with highrisk patients (those with pT3/4 and/or pN+ disease) who did not receive preoper ative treatment regarding the potential risks and benefits associated with adjuvant chemotherapy, and limitations of the available data on this approach 13 . Incremental advances have been made over the past decade in improving the tolerability and effec tiveness of systemic chemotherapy regimens; however, new molecular profiling technologies and advances in immunotherapy are poised to dramatically reshape the therapeutic landscape for patients with MIBC. An improved understanding of the genomic makeup of MIBC, including somatic mutations in DNArepair genes and intrinsic subtypes defined by unique geneexpression profiles, might enable a personalized approach to chemo therapy. Although outside the scope of this Review, the identification of driver mutations that can be targeted with selective inhibitors might also be of relevance to therapy for MIBC, as in other malignancies 147, 148 . Finally, blockade of the PD1-PDL1 axis might be a transform ative approach in MIBC, by harnessing the power of antitumor immunity to obtain durable clinical benefit. Nevertheless, the future of immunecheckpoint block ade will probably involve combinationbased approaches using established therapeutic modalities, novel immuno therapeutic strategies, or both. Coordinated efforts will be needed to determine the optimal therapeutic com binations and to apply both immuneprofiling and genomicprofiling technologies to expand our predictive abilities beyond PDL1 expression.
